Qubigen Launches Collaborative Federated AI Antiviral Drug Design Project
- Apr 29
- 3 min read
Qubigen is pleased to announce the launch of a new collaborative Federated AI drug design project focused on the development of novel antiviral small molecules for emerging infectious diseases. This initiative reflects Qubigen’s commitment to shortening development timelines and advancing next-generation drug discovery through secure, collaborative AI technologies.
Enabling Secure Multi-Party Drug Design with Qubigen’s FedAIDD
This multi-party initiative consists of nonprofit organizations, academic institutions, and industry partners, bringing together complementary contributions across antiviral discovery, computational design, and translational drug development efforts. A key component of the project is Qubigen’s Federated AI for Drug Design (FedAIDD) platform, which was designed to enable secure multi-party learning across distributed datasets while preserving data privacy and intellectual property boundaries. The platform brings together proprietary and public data sources in a collaborative framework designed to support the generation of new candidate molecules, without requiring participating organizations to expose sensitive underlying data.
Global Collaboration Across Leading Research Institutions
A key collaborator in this antiviral initiative is the Institute of Microbial Chemistry (IMC), a research institute of the Microbial Chemistry Research Foundation in Japan, which brings longstanding expertise in natural product-based discovery and bioactive compound research. For this project, IMC is contributing antiviral data and scientific insights relevant to infectious disease drug discovery. The broader initiative also draws on relevant antiviral data provided by the Institute of Virology at Philipps University of Marburg through its Nucleoside Booster program, in partnership with DNDi and the German Center for Infection Research (DZIF). Qubigen will apply its FedAIDD platform to generate novel small-molecule candidates with improved antiviral activity and more favorable synthetic feasibility, while also contributing its own proprietary ADMET database to improve drug-like properties. Potential avenues for downstream development and commercialization with an industry partner are also being explored.
Federated Discovery of Promising Antiviral Compounds
To date, relevant datasets have been curated and uploaded to the secure FedAIDD platform, and Qubigen has commenced AI-driven design runs to generate novel candidate molecules, tailored for antiviral activity. The goal is to identify promising new chemical matter that can be prioritized for synthesis and biological validation, with lead candidates advanced to preclinical evaluation and further development. This multi-party collaboration highlights a key capability of Qubigen’s FedAIDD platform: combining partner data, curated internal resources, and AI-guided compound generation to support novel molecule design in a way that no single organization could achieve on its own. In this way, Qubigen’s technology can help accelerate drug design in areas of high unmet medical need, without exposing secrets.
Qubigen looks forward to sharing further updates as the project progresses.
About MCRF
The Microbial Chemistry Research Foundation (MCRF) was established as a non-profit incorporated foundation in 1958 with the proceeds from the research results of the anti-tuberculosis drug Kanamycin. In 1962, the Institute of Microbial Chemistry (IMC) was founded as a dedicated research institute. Since then, they have contributed to the health and well-being of humanity and the advancement of science and technology through the discovery and development of antibiotics and other biologically active substances derived from microorganisms. Carrying forward the spirit of their founding, they continue to promote basic research including the diverse and effective uses of microorganisms. Building on these findings, they also pursue applied research aimed at developing new substances that enhance human health and welfare, and strive to bring these innovations into practical use in society.
German Center for Infection Research (DZIF)
At the German Center for Infection Research (DZIF), more than 700 scientists from 35 institutions nationwide jointly develop new approaches for the prevention, diagnosis and treatment of infectious diseases. Their aim is to translate research results into clinical practice rapidly and effectively. With this, the DZIF paves the way for developing new vaccines, diagnostics and drugs in the fight against infections. The DZIF is one of eight centers in the German Centers for Health Research (DZG) network.
Further information about the DZIF: www.dzif.de and the DZG: www.deutschezentren.de
Qubigen Accelerate Drug Design Without Exposing Secrets
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.
